Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® for Pediatric Patients with Functional Constipation

Ironwood Pharmaceuticals has announced that LINZESS has been approved by the US Food and Drug Administration (FDA) as a once-daily treatment for functional constipation in pediatric patients aged six to 17 years old. Functional constipation is a chronic condition characterized by hard, infrequent bowel movements that are often difficult or painful to pass, affecting an estimated six million chil..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 13.
  • textsms

FDA Action Alert: BMS, GSK, Ironwood, Ipsen/Albireo

The FDA has four target action dates this week, including approvals for drugs to treat functional constipation, Alagille syndrome, myelofibrosis and symptomatic obstructive hypertrophic cardiomyopathy. Ironwood Pharmaceuticals' Linzess is set to be approved as a treatment for functional constipation in children aged 6-17 years on June 14th. Albireo's Bylvay may also receive approval on June 15th..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 13.
  • textsms